Inventor · disambiguated record
Federica Sotgia
Also filed as: SOTGIA FEDERICA
28 granted patents·21 pending applications·14 citations·filing 2010–2025
93Inventor score
Top patents by PatentIndex Score
49 records- 0193US12208111B2Azithromycin and roxithromycin derivtives as senolytic drugsLUNELLA BIOTECH INC·Filed 2024·Granted Jan 28, 2025·1 cites·8 claims
- 0291US10512618B2Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeastLUNELLA BIOTECH INC·Filed 2018·Granted Dec 24, 2019·4 cites·8 claims
- 0387US10980821B2Triphenylphosphonium-derivative compounds for eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2018·Granted Apr 20, 2021·2 cites·27 claims
- 0485US11364210B2Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria and pathogenic yeastLUNELLA BIOTECH INC·Filed 2019·Granted Jun 21, 2022·1 cites·9 claims
- 0584US11957700B2Azithromycin and roxithromycin derivatives as senolytic drugsLUNELLA BIOTECH INC·Filed 2019·Granted Apr 16, 2024·1 cites·14 claims
- 0683US11547679B2Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria and pathogenic yeastLUNELLA BIOTECH INC·Filed 2019·Granted Jan 10, 2023·1 cites·3 claims
- 0782US11672810B2Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancerLUNELLA BIOTECH INC·Filed 2020·Granted Jun 13, 2023·1 cites·30 claims
- 0881US11311501B2Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeastLUNELLA BIOTECH INC·Filed 2018·Granted Apr 26, 2022·1 cites·9 claims
- 0981US2025120994A1Azithromycin and roxithromycin derivatives as senolytic drugsLUNELLA BIOTECH INC·Filed 2024·Application pending·0 cites
- 1078US12006553B2Companion diagnostics for mitochondrial inhibitorsLUNELLA BIOTECH INC·Filed 2018·Granted Jun 11, 2024·1 cites·9 claims
- 1177US2024316086A1Triple combination therapies for anti-agingLUNELLA BIOTECH INC·Filed 2024·Application pending·0 cites
- 1274US11229657B2Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapyLUNELLA BIOTECH INC·Filed 2018·Granted Jan 25, 2022·1 cites·16 claims
- 1374US2024116942A1Selective cdk 4/6 inhibitor cancer therapeuticsLUNELLA BIOTECH INC·Filed 2023·Application pending·0 cites
- 1471US11918597B2Triple combination therapies for anti-agingLUNELLA BIOTECH INC·Filed 2019·Granted Mar 5, 2024·0 cites·16 claims
- 1571US11865124B2Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCS)LUNELLA BIOTECH INC·Filed 2021·Granted Jan 9, 2024·0 cites·8 claims
- 1671US11865130B2Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2021·Granted Jan 9, 2024·0 cites·17 claims
- 1770US11964983B2Selective CDK4/6 inhibitor cancer therapeuticsLUNELLA BIOTECH INC·Filed 2021·Granted Apr 23, 2024·0 cites·5 claims
- 1870US2022339125A1Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeastLUNELLA BIOTECH INC·Filed 2022·Application pending·0 cites
- 1969US11738034B2Triphenylphosphonium-derivative compounds for eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2021·Granted Aug 29, 2023·0 cites·18 claims
- 2067US11197872B2Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)LUNELLA BIOTECH INC·Filed 2018·Granted Dec 14, 2021·0 cites·6 claims
- 2166US2022096502A1Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapyLUNELLA BIOTECH INC·Filed 2021·Application pending·0 cites
- 2265US11160821B2Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2018·Granted Nov 2, 2021·0 cites·6 claims
- 2364US11441195B2Energetic cancer stem cells (e-CSCs): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energyLUNELLA BIOTECH INC·Filed 2019·Granted Sep 13, 2022·0 cites·25 claims
- 2463US11497749B2Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respirationLUNELLA BIOTECH INC·Filed 2018·Granted Nov 15, 2022·0 cites·19 claims
- 2563US2025304591A1SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES AS SELECTIVE CDK 4/6 INHIBITORSLUNELLA BIOTECH INC·Filed 2025·Application pending·0 cites
- 2663US2025206713A12-[(2-oxo-4-phenyl-2h-chromen-7-yl)oxy] propanamido derivativesLUNELLA BIOTECH INC·Filed 2023·Application pending·0 cites
- 2762US11667639B2Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cellsLUNELLA BIOTECH INC·Filed 2018·Granted Jun 6, 2023·0 cites·7 claims
- 2862US11561227B2Anti-mitochondrial inhibitors for oncogenic Ras and MycLUNELLA BIOTECH INC·Filed 2018·Granted Jan 24, 2023·0 cites·10 claims
- 2961US12358920B2Substituted pyrrolo[2,3-d]pyrimidines as selective CDK 4/6 inhibitorsLUNELLA BIOTECH INC·Filed 2020·Granted Jul 15, 2025·0 cites·19 claims
- 3061US11667640B2Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cellsLUNELLA BIOTECH INC·Filed 2020·Granted Jun 6, 2023·0 cites·6 claims
- 3157US2014221496A1Method of Diagnosis or Prognosis of a Neoplasm Comprising Determining the Level of Expression of a Protein in Stromal Cells Adjacent to the NeoplasmUNIV JEFFERSON·Filed 2013·Application pending·0 cites
- 3257US2025049823A1Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasisLUNELLA BIOTECH INC·Filed 2022·Application pending·0 cites
- 3356US2016139132A1Method of Diagnosis or Prognosis of a Neoplasm Comprising Determining the Level of Expression of a Protein in Stromal Cells Adjacent to the NeoplasmUNIV JEFFERSON·Filed 2015·Application pending·0 cites
- 3455US2023172879A1Therapeutic methods for preventing tumor metastasis and tumor recurrenceLUNELLA BIOTECH INC·Filed 2021·Application pending·0 cites
- 3554US11559527B2Targeting mitochondrial fission through mDIVI-1 derivativesLUNELLA BIOTECH INC·Filed 2018·Granted Jan 24, 2023·0 cites·8 claims
- 3653US12188936B2Biomarkers and therapeutics for endocrine therapy resistanceLUNELLA BIOTECH INC·Filed 2019·Granted Jan 7, 2025·0 cites·35 claims
- 3752US11497759B2Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2018·Granted Nov 15, 2022·0 cites·17 claims
- 3852US2024010622A1Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasisLUNELLA BIOTECH INC·Filed 2021·Application pending·0 cites
- 3950US2022249438A1Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cellsLUNELLA BIOTECH INC·Filed 2020·Application pending·0 cites
- 4050US2023174464A1Myristoyl derivatives of 9-amino-doxycycline for targeting cancer stem cells and preventing metastasisLUNELLA BIOTECH INC·Filed 2021·Application pending·0 cites
- 4149US12319690B2Selective CDK 4/6 inhibitor cancer therapeuticsLUNELLA BIOTECH INC·Filed 2020·Granted Jun 3, 2025·0 cites·15 claims
- 4249US2022211728A1Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatmentsLUNELLA BIOTECH INC·Filed 2020·Application pending·0 cites
- 4349US2022040316A1Triple combination therapies for targeting mitochondria and killing cancer stem cellsLUNELLA BIOTECH INC·Filed 2019·Application pending·0 cites
- 4448US2012190565A1Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The NeoplasmLISANTI MICHAEL P·Filed 2010·Application pending·0 cites
- 4547US2022365069A1Atp-based cell sorting and hyperproliferative cancer stem cellsLUNELLA BIOTECH INC·Filed 2020·Application pending·0 cites
- 4643US10085987B2MCT protein inhibitor-related prognostic and therapeutic methodsUNIV JEFFERSON·Filed 2013·Granted Oct 2, 2018·0 cites·2 claims
- 4742US2014322705A1Cancer diagnostic and cancer therapeuticLISANTI MICHAEL P·Filed 2011·Application pending·0 cites
- 4842US2013172430A1Prognosis and treatment of breast cancerLISANTI MICHAEL P·Filed 2011·Application pending·0 cites
- 4938US2012039805A1Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell SampleLISANTI MICHAEL P·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Federica Sotgia files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →